Ministry : Insurance Regulatory And Development Authority (Not Applicable)
Part III-Section 4
Subject : Extra Ordinary
Analysis of the Government Gazette (based on the title and content)
The document comprises multiple notifications issued by the Central Government of India under the Drugs and Cosmetics Act, 1940, specifically exercising powers under Section 26A. These notifications, published in the Extraordinary edition of the Gazette of India on June 11, 2026, announce the immediate prohibition of several fixed-dose combinations (FDCs) of drugs. The decisions are based on recommendations from an Expert Committee (reviewed in 2021) and the Drugs Technical Advisory Board (DTAB), which concluded that these FDCs lack therapeutic justification, have no pharmacological rationale, and pose potential risks when safer alternatives exist.
Summary
The Government Gazette notifications prohibit the manufacture, sale, and distribution of six fixed-dose combinations of drugs across various therapeutic categories. The bans are enacted due to irrational combinations, lack of scientific evidence, absence of clinical justification, and availability of safer alternatives. The affected drugs include combinations involving acetylated salicylic acid, etheophylline, doxylamine, levocetirizine, aloe vera, vitamin E, dimethicone, gliclazide, chromium picolinate, cefadroxil, cefuroxime, and others. The immediate effect of these prohibitions aims to enhance public safety and ensure rational pharmacotherapy in accordance with national and international treatment guidelines.
Key Points
- Six separate notifications (GI/2026/3, GI/2026/4, GI/2026/5, GI/2026/6, GI/2026/7, GI/2026/8) were issued on June 11, 2026.
- All notifications follow the same procedural framework: Expert Committee review (2021), DTAB approval, Sub-Committee examination, public stakeholder input, and final government order.
- Prohibited FDCs include:
- Acetyl Salicylic Acid + Ethoheptazine
- Aloe Vera + Jojoba Oil + Wheat Germ Oil + Tea Tree Oil
- Dicyclomine + Paracetamol + Clidinium Bromide + Chlordiazepoxide
- Aloe Extract + Vitamin E + Dimethicone + Glycerine
- Etheophylline + Cetirizine
- Cefadroxil + Probenecid, Cefuroxime + Serratiopeptidase, and Sefadroxil + Serratiopeptidase
- Common reasons for prohibition:
- No therapeutic justification or pharmacological rationale.
- Inconsistency with standard treatment guidelines.
- Lack of valid clinical or scientific evidence.
- Risk to human health when safer alternatives are available.
- The bans are effective with immediate notice (June 11, 2026).
Summary (Concise)
The Government of India has banned six fixed-dose drug combinations under Section 26A of the Drugs and Cosmetics Act, 1940, following expert committee recommendations that found these formulations to be therapeutically unjustified, scientifically unsupported, and potentially hazardous. The prohibited combinations involve common drugs for pain, allergies, respiratory conditions, dermatological use, and gastrointestinal disorders. The immediate enforcement aims to promote rational prescribing and ensure public safety by eliminating ineffective and potentially harmful FDCs from the market.
